Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 14/20 | 0.68 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008341 | 0.93 | GRM1 (0.71) | GRM1GRIA2ALDH1A1HPGDMEN1 | |
| SCHEMBL1006807 | 0.89 | GRM1 (0.63) | GRM1GRIA2ALDH1A1HPGDMEN1 | |
| SCHEMBL4152901 | 0.88 | GRM1 (0.81) | GRM1GRIA2ALDH1A1HPGDMEN1 | |
| SCHEMBL13108851 | 0.84 | GRM1 (0.67) | GRM1GRIA2ALDH1A1HPGDMEN1 | |
| SCHEMBL1007297 | 0.83 | GRM1 (0.87) | GRM1GRIA2ALDH1A1HPGDMEN1 | |
| SCHEMBL1007515 | 0.82 | GRM1 (0.65) | GRM1GRIA2ALDH1A1HPGDMEN1 | |
| SCHEMBL3452464 | 0.82 | GRM1 (0.60) | GRM1GRIA2ALDH1A1HPGDMEN1 | |
| SCHEMBL3452157 | 0.82 | GRM1 (0.75) | GRM1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL1007269 | 0.81 | GRM1 (1.00) | GRM1GRIA2ALDH1A1HPGDMEN1 | |
| SCHEMBL13108879 | 0.79 | GRM1 (0.68) | GRM1GRIA2ALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | GRM1 2/4885GRIA2 23/4885ALDH1A1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.